Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis

PURPOSE: Many immune checkpoint inhibitors (ICIs) have been approved on the basis of tumor response end points in nonrandomized trials, including objective response rate (ORR) and duration and depth of response. We aimed to assess the validity of these end points as surrogate end points for overall...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JCO Precis Oncol
Asıl Yazarlar: Kok, Peey-Sei, Yoon, Won-Hee, Lord, Sally, Marschner, Ian, Friedlander, Michael, Lee, Chee Khoon
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wolters Kluwer Health 2021
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8289006/
https://ncbi.nlm.nih.gov/pubmed/34296055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.21.00108
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller